{"schema_version":"secwatch.filing_event.v1","accession":"0000917520-23-000035","form_type":"8-K","ticker":"IART","cik":"0000917520","company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","filed_at":"2023-05-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.801339+00:00","generated_at":"2026-06-14T17:45:44.524921+00:00","sec_items":["2.06","7.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Integra LifeSciences initiates global product recall due to endotoxin issues, cuts guidance","bullets":["Voluntary recall of SurgiMend, PriMatrix, Revize, TissueMend from Boston facility (March 2018 – May 2023).","Expects $22M inventory impairment charge in Q2 ending June 30, 2023; no cash impact.","Q2 2023 guidance revised: revenue $372M-$376M, adjusted EPS $0.55-$0.59.","If stoppage continues through 2023, full-year revenue impact ~$60M, EPS ~$0.35.","Boston facility products represent ~5% of consolidated revenues; manufacturing halt extended."],"urls":{"canonical":"https://secwatch.observer/filing/0000917520-23-000035","json":"https://secwatch.observer/filing/0000917520-23-000035.json","markdown":"https://secwatch.observer/filing/0000917520-23-000035.md","text":"https://secwatch.observer/filing/0000917520-23-000035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/917520/000091752023000035/0000917520-23-000035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/917520/000091752023000035/iart-20230522.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T17:45:44.524921+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a329f51507a95eb586dbe8cae2be3ddea5e16b3b","claim":"INTEGRA LIFESCIENCES HOLDINGS CORP announced a impairment with charges of approximately $22 million affecting Boston, Massachusetts facility.","evidence_excerpt":"Integra LifeSciences Holdings Corporation (the “Company”), after consultation with the U.S. Food and Drug Administration (the “FDA”), initiated a voluntary global recall of all products manufactured in its Boston, Massachusetts facility (the “Boston facility”) distributed between March 1, 2018 and May 22, 2023 (the “voluntary recall”). As a result, the Company concluded on May 22, 2023 that it expects it will incur an impairment charge related to the write-off of inventories, net, of approximately $22 million.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/917520/000091752023000035/0000917520-23-000035-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"impairment"},{"label":"Charge","value":"approximately $22 million"},{"label":"Affected area","value":"Boston, Massachusetts facility"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}